Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine

Headache. 2019 Apr;59(4):627-628. doi: 10.1111/head.13514.

Authors

Noah Rosen¹, Eric Pearlman², Dustin Ruff², Kathleen Day², Abraham Jim Nagy³

Affiliations

¹ Department of Neurology, Hofstra Northwell School of Medicine at Hofstra University, Hempstead, NY, USA.
² Eli Lilly and Company, Indianapolis, IN, USA.
³ Nevada Headache Institute, Las Vegas, NV, USA.

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Double-Blind Method
Humans
Migraine Disorders*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
galcanezumab